Today Orexo is a fully integrated pharmaceutical company where research and development is conducted in Uppsala, Sweden. The US business contributes with increasingly more profit and cash and enables further development of the business.


Orexo’s business model is based on two cornerstones – the American commercial platform that commercializes Zubsolv® in the US today and the research and development organization in Uppsala, Sweden, which works on developing new products for the treatment of addiction. This business model has proved to be profitable over the past two years and today revenues fully finance investments in the in-house development projects.